Docetaxel and paclitaxel in the treatment of breast cancer: a review of clinical experience.
about
Anti-Invasive and Anti-Proliferative Synergism between Docetaxel and a Polynuclear Pd-Spermine AgentRegulation of mitosis and taxane response by Daxx and Rassf1.Paclitaxel loading in PLGA nanospheres affected the in vitro drug cell accumulation and antiproliferative activity.Model-based meta-analysis for quantifying Paclitaxel dose response in cancer patients.Micro-RNAs as Potential Predictors of Response to Breast Cancer Systemic Therapy: Future Clinical Implications.Rotational-echo double-resonance NMR distance measurements for the tubulin-bound Paclitaxel conformationBiological assessment of triazine dendrimer: toxicological profiles, solution behavior, biodistribution, drug release and efficacy in a PEGylated, paclitaxel constructIntratumoral injection of taxol in vivo suppresses A549 tumor showing cytoplasmic vacuolization.Docetaxel-loaded solid lipid nanoparticles suppress breast cancer cells growth with reduced myelosuppression toxicityTopoisomerase II alpha and TLE3 as predictive markers of response to anthracycline and taxane-containing regimens for neoadjuvant chemotherapy in breast cancer.Superior antitumor activity of nanoparticle albumin-bound paclitaxel in experimental gastric cancer.Antimitotic chemotherapeutics promote adhesive responses in detached and circulating tumor cellsValidating the use of a luciferase labeled breast cancer cell line, MDA435LCC6, as a means to monitor tumor progression and to assess the therapeutic activity of an established anticancer drug, docetaxel (Dt) alone or in combination with the ILK inhSecond generation benzofuranone ring substituted noscapine analogs: synthesis and biological evaluationHuman GM3 Synthase Attenuates Taxol-Triggered Apoptosis Associated with Downregulation of Caspase-3 in Ovarian Cancer Cells.Human beta-galactoside alpha-2,3-sialyltransferase (ST3Gal III) attenuated Taxol-induced apoptosis in ovarian cancer cells by downregulating caspase-8 activity.Role of chemotherapy in breast cancer.Spontaneously-forming spheroids as an in vitro cancer cell model for anticancer drug screeningSafety Results of Docetaxel-(Taxotere®)-Based Chemotherapy in Early Breast Cancer Patients of Asia-Pacific Region: Asia-Pacific Breast Initiative II.Predictive factors for response to docetaxel in human breast cancers.The therapeutic potential of a series of orally bioavailable anti-angiogenic microtubule disruptors as therapy for hormone-independent prostate and breast cancers.Improved biochemical strategies for targeted delivery of taxoidsA leukotriene B4 receptor-2 is associated with paclitaxel resistance in MCF-7/DOX breast cancer cellsSuperToxic: a comprehensive database of toxic compoundsBreast cancer cells evade paclitaxel-induced cell death by developing resistance to dasatinib.TLE3 as a candidate biomarker of response to taxane therapy.Thick-tissue bioreactor as a platform for long-term organotypic culture and drug delivery.Far-Red Light-Activatable Prodrug of Paclitaxel for the Combined Effects of Photodynamic Therapy and Site-Specific Paclitaxel Chemotherapy.Fulminating septic shock from Clostridium perfringens in an early breast cancer patient with severe myalgia after docetaxel treatment.Description of anaphylactic reactions to paclitaxel and docetaxel reported to the FDA, with a focus on the role of premedication.Docetaxel nanotechnology in anticancer therapy.Structural studies of taxol analogues for drug discovery.Anticancer activity of Saussurea lappa extract by apoptotic pathway in KB human oral cancer cells.Pharmaceuticals that contain polycyclic hydrocarbon scaffolds.Genomic signatures for paclitaxel and gemcitabine resistance in breast cancer derived by machine learning.Cell death response to anti-mitotic drug treatment in cell culture, mouse tumor model and the clinicDesign and synthesis of simplified taxol analogs based on the T-Taxol bioactive conformation.Effectiveness of liposomal paclitaxel against MCF-7 breast cancer cells.A phase I dose escalation study of TTI-237 in patients with advanced malignant solid tumors.Controlled drug release to cancer cells from modular one-photon visible light-responsive micellar system
P2860
Q28553698-8905B1D9-00B1-430E-95A5-EA5A875A5C3CQ30574064-5C0CFE4E-042A-4BA8-9C19-8428D596F6BFQ33355378-D4C764E9-0BF0-47A5-8CFD-030839E58025Q33749066-BD92CD8F-6D93-4107-BBDD-50ADDE79B602Q33838622-FD0FEA01-24AC-4CBC-B33C-93511EF5920EQ34001846-593B5527-AF8F-4295-B8C1-18B0E547E7F8Q34038519-E8C5F472-2C5A-438E-AB02-113B1B4A360EQ34089072-5BD30C6F-422B-4D5D-B4A3-01ED84A7BDF8Q34394402-5A4DAF0A-16E6-4042-BEA4-7E2FAA899689Q34555411-377B2184-8314-4C93-B06D-4B71B496A1F2Q34608899-A68EE501-C225-4C04-AEF5-63648A239922Q34991861-ACEA584E-B02C-4FC0-93FA-BC38A02B685DQ35001420-A849997A-8985-407A-B2AA-A8EAEB49840AQ35231775-417C7C41-0FF8-4B52-BAF4-DA9DC289DD62Q35445963-F5A40E04-E41F-4FFD-9E58-2001C813A313Q35668911-915EE2E8-963A-41B6-91DA-6A5E488D6C3EQ36334921-713E19CE-4A81-4795-9351-64A356702451Q36356303-794CDFC8-8BC1-4F89-906A-86CC3127F83BQ36441535-29851775-0015-4D7F-88CD-24B8E9BFD7CEQ36521963-95C33F5D-F300-429A-920B-0F6413F3DF2FQ36610771-2712BE5A-CA49-4A64-9BB8-C2ECF615E275Q36642502-98059655-DE43-4EA5-8F88-99C133674335Q37040640-E0144D9E-3DA4-4C40-8FFE-0CAC7F1E82BBQ37202625-68308A51-61B9-4FBA-8984-E921A29C752DQ37205970-C5EF980D-D5AD-4D01-8C51-968A1B4549DFQ37208764-D3B98784-AC16-46C5-9E62-2D8E416CE27AQ37305892-FC37845B-F59C-45D6-B237-48908759FE16Q37367650-28F79041-CFEF-4505-BAAD-CA734FEFAD07Q37694174-8BA2A480-92D7-4571-BCBB-11343FAB1EFAQ37877271-DE697815-A790-4D08-9771-69ABC339F4BCQ38003964-8271A75F-346B-49DD-B609-EF4BB3057FCFQ38090681-08837A94-B152-42DB-A7F2-FA2915AFF996Q38448690-B61EE1A1-BA2C-40E9-829E-57FA12FFF5FCQ38546598-0942218D-7D8A-4216-8666-6C8EF73D46E3Q38835169-5145ADB7-EFF5-47FD-8198-7127A6BA7DF7Q38935027-EA74CFDE-7D6D-4EF6-94DA-5710222E643FQ39425105-01839D3A-BC73-4CFE-94CB-2DEC728E6818Q39619164-1168A21D-A036-488A-96F6-D54DCE95BEBDQ40351640-D95EC042-695D-4A34-8976-F47FA4223327Q41042647-29BB5F04-B50E-4306-8395-8A73F64F91E1
P2860
Docetaxel and paclitaxel in the treatment of breast cancer: a review of clinical experience.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Docetaxel and paclitaxel in th ...... review of clinical experience.
@ast
Docetaxel and paclitaxel in th ...... review of clinical experience.
@en
type
label
Docetaxel and paclitaxel in th ...... review of clinical experience.
@ast
Docetaxel and paclitaxel in th ...... review of clinical experience.
@en
prefLabel
Docetaxel and paclitaxel in th ...... review of clinical experience.
@ast
Docetaxel and paclitaxel in th ...... review of clinical experience.
@en
P2093
P1433
P1476
Docetaxel and paclitaxel in th ...... review of clinical experience.
@en
P2093
John Crown
Michael O'Leary
Wei-Seong Ooi
P356
10.1634/THEONCOLOGIST.9-SUPPL_2-24
P478
P577
2004-01-01T00:00:00Z